跳至主要内容
临床试验/EUCTR2020-002905-24-NL
EUCTR2020-002905-24-NL进行中(未招募)1 期

Efficacy and feasibility of intranasal ketamine on acute suicidality, a double blindrandomized placebo-controlled trial(Ketamine Trial for Acute suicidalty, KETA) - Ketamine Trial for Acute suicidality (KETA)

niversity Medical Center Groningen0 个研究点目标入组 112 人开始时间: 2021年6月10日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
112

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Acute suicidality
  • A Beck Scale for Suicide Ideation (BSSI)-score of 7 or above
  • Subjects are in the age of 18-7
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 112
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Earlier participation in this study
  • 2. Psychosis (as a primary diagnosis) (depression with psychotic features will not be an exclusion criterion per se).
  • 3. A diagnosis of schizophrenia or another primary psychotic disorder.
  • 4. A history of PCP- or ketamine addiction.
  • 5. Being under influence of GHB (Substance abuse in the (recent) history
  • is not an exclusion criterion per se (with the exception of GHB and a high
  • blood alcohol concentration, and intoxications leading to medical
  • unstable conditions).
  • 6. A blood alcohol concentration (BAC)of >0.05%
  • 7. A clinically significant and unstable infectious, immunological,
  • cardiovascular, gastro-intestinal, pulmonal, renal, hepatic, endocrine or haematological disorder, a myocardial infarction, miction problems or a complex surgical problem that needs immediate attention.
  • 8. Presence of any contra-indication for ketamine use, such as severe high blood pressure, a recent myocardial infarction or relevant cardiac problems, severe thyroid problems, severe liver problems, severe kidney problems, epilepsy and increased intracranial pressure.
  • 9. A known hypersensitivity for ketamine.
  • 10. Concomitant use of a MAO-inhibitor.
  • 11. Severe nose congestion or nasal polyps.
  • 12. Pregnancy or giving breastfeeding 13. Women of reproductive age using unreliable contraception.
  • 14. Being unable to answer the questionnaires
  • 15. Legal incompetency with regard to participation in this study
  • 16. No informed consent

研究者

相似试验